Literature DB >> 10644845

Identification of a human epitope in hepatitis C virus (HCV) core protein using a molecularly cloned antibody repertoire from a non-symptomatic, anti-HCV-positive patient.

V Barban1, S Fraysse-Corgier, G Paranhos-Baccala, M Petit, C Manin, Y Berard, A M Prince, B Mandrand, P Meulien.   

Abstract

Healthy carriers of hepatitis C virus (HCV) infection exhibit a specific antibody response against all HCV antigens, which could play a role in disease control. Generation of panels of human antibodies may permit a thorough characterization of this response and further identify particular antibodies with potential clinical value. To this effect, we have established a human phage-display antibody library from a patient exhibiting a high antibody response against HCV antigens and no clinical symptoms of disease. This library was screened against a recombinant core antigen [amino acids (aa) 1-119] produced in E. coli. Two recombinant Fab-carrying phages (rFabCs) were isolated and characterized. Both rFabC3 and rFabC14 recognize aa 1-48 on core antigen, but rFabC14 is competed out by a synthetic peptide, C(2-20) (aa 1-20), at much lower concentrations than rFabC3. In order to identify more precisely the recognition sites of these antibodies, we produced soluble forms of the rFabs (sFabs), and used them to pan a random phage-display peptide library. A single peptide sequence, QLITKPL, was identified with sFabC3, while two equally represented sequences, HAFPHLH and SAPSSKN, were isolated using sFabC14. The QLITKPL sequence was partially localized between aa 8 and 14 of core protein, but no clear homology was found for the two sFabC14 peptides. However, we confirmed the specificity of these peptides by competition experiments with sFabC14.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10644845     DOI: 10.1099/0022-1317-81-2-461

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  6 in total

1.  Preparation of single chain variable fragment of MG(7) mAb by phage display technology.

Authors:  Z C Yu; J Ding; Y Z Nie; D M Fan; X Y Zhang
Journal:  World J Gastroenterol       Date:  2001-08       Impact factor: 5.742

Review 2.  Developing Recombinant Antibodies by Phage Display Against Infectious Diseases and Toxins for Diagnostics and Therapy.

Authors:  Kristian Daniel Ralph Roth; Esther Veronika Wenzel; Maximilian Ruschig; Stephan Steinke; Nora Langreder; Philip Alexander Heine; Kai-Thomas Schneider; Rico Ballmann; Viola Fühner; Philipp Kuhn; Thomas Schirrmann; André Frenzel; Stefan Dübel; Maren Schubert; Gustavo Marçal Schmidt Garcia Moreira; Federico Bertoglio; Giulio Russo; Michael Hust
Journal:  Front Cell Infect Microbiol       Date:  2021-07-07       Impact factor: 5.293

3.  Characterization of differential antibody production against hepatitis C virus in different HCV infection status.

Authors:  Mona Rafik; Salwa Bakr; Dina Soliman; Nesrine Mohammed; Dina Ragab; Walid Abd ElHady; Nancy Samir
Journal:  Virol J       Date:  2016-06-30       Impact factor: 4.099

4.  Comparative Immunogenicity in Rabbits of the Polypeptides Encoded by the 5' Terminus of Hepatitis C Virus RNA.

Authors:  Irina Sominskaya; Juris Jansons; Anastasija Dovbenko; Natalia Petrakova; Ilva Lieknina; Marija Mihailova; Oleg Latyshev; Olesja Eliseeva; Irina Stahovska; Inara Akopjana; Ivars Petrovskis; Maria Isaguliants
Journal:  J Immunol Res       Date:  2015-11-02       Impact factor: 4.818

Review 5.  Infectious disease antibodies for biomedical applications: A mini review of immune antibody phage library repertoire.

Authors:  Jing Yi Lai; Theam Soon Lim
Journal:  Int J Biol Macromol       Date:  2020-07-08       Impact factor: 6.953

Review 6.  Recombinant antibodies for diagnostics and therapy against pathogens and toxins generated by phage display.

Authors:  Philipp Kuhn; Viola Fühner; Tobias Unkauf; Gustavo Marcal Schmidt Garcia Moreira; André Frenzel; Sebastian Miethe; Michael Hust
Journal:  Proteomics Clin Appl       Date:  2016-06-21       Impact factor: 3.494

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.